Accelerate research, empower industry

CRISPR/Cas9-mediated gene knockout (KO)CRISPR/Cas9-mediated gene knockin (KI)CRISPR/Cas9-mediated gene point-mutationInducible Gene Over-expression (Tet-On)shRNA Knockdown cell serviceCRISPR-KO libraryCRISPRa libraryCRISPRi libraryCRISPRSeek™ library screening serviceCRISPRSeek™ Library PlasmidCRISPRSeek™ Library VirusCRISPRSeek™ Library Cell PoolCRISPRSeek™ Library ProductsHySigen Vector LibraryVB163VB164VB203VB204VB205VB303VB271VB272VB188VB278VB180VB251VB252Custom Vector Construction ServiceCustom Vector Construction Service-1Lentivirus PackagingshRNA AAVAdeno-Associated Virus (AAV) PackagingOver-expression AAVIn-stock virusesVirus PackagingCustomized Peptide SynthesisHuman cell linesAnimal cell linesCell LinesKO cell linesPoint mutation cell linesKI cell linesFluorescence-tag cell linesStable cell linesOff-the-shelf gene-edited cell linesOne-step freezing medium for stem cellsOne-step freezing medium for PBMCsCell freezing mediaOsteogenic differentiation culture mediumAdipogenic differentiation culture mediumChondrogenic differentiation culture mediumStem cell differentiation mediaStem cell culture mediaKnockout Cell LinesKnockin Cell LinesPoint mutation cell lineInducible Gene ExpressionGenome-Wide Libraries at Unbeatable PricesWho we arePartnersDistributorsTechnical PlatformsNews & eventsPublicationsResourcesPrivacy policySupportContact UsSubmitted successfully
插件代码
mLdha knockout 4T1 cell line
mLdha knockout 4T1 cell line 
Price：
$2,999.00
Cat.No.：
Size：
Quantity：
Order
Product info
Documents
References
Cat.No.： CGKO-M2899 Size： 1x10^6

HyCyte Cell Line: HyCyte 4T1 KO-mLdha

Parental: 4T1

Catalogue No.: CGKO-M2899

Species: Mouse

Gene: mLdha

Gene ID: 16828

Passage: 9

Doubling time: 48-72 h

Growth Properties: Adherent

Clone Type: Homozygote

Recommended culture media:

RPMI-1640 supplemented with 10 % FBS, 100 U/ml Penicilin and 100 µg/ml

Streptomycin (HyCyte,TCM-G705).

Subculture: Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 2-3 days. Split at 80-85% confluency, approximately 1:3-1:6.

Freezing media: RPMI-1640 + 30 % FBS + 10 % DMSO;or One Step Freezing Medium(HyCyte, GUCP-R201).

Genotype: mLdha (-/-)

Quality test: Bacteria, fungi and mycoplasma negative

COA Simple-Set-of-Stationery-Related-Vector-Line-Icons 1.svg

Pulaski BA, et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol. Immunother. 49: 34-45, 2000. PubMed: 10782864.

Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493, 1998. PubMed: 9537252.

Pulaski BA, et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 60: 2710-2715, 2000. PubMed: 10825145.

Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405, 1992. PubMed: 1540948.


IF=12.4 Zhang Z, Tang S, Qi M, et al. Mitochondria-targeting natural product rhein conjugated with dichloroacetate as the dual inhibitor of glycolysis and oxidative phosphorylation to off energize cancer cells and induce ROS storm[J]. Theranostics, 2025, 15(11): 4909.

IF=18 Wang Z, Sha T, Li J, et al. Turning foes to friends: Advanced “in situ nanovaccine” with dual immunoregulation for enhanced immunotherapy of metastatic triple-negative breast cancer[J]. Bioactive Materials, 2024, 39: 612-629.

IF=14.3 Fu J, Wu S, Bao N, et al. A Universal Strategy of Anti‐Tumor mRNA Vaccine by Harnessing “Off‐the‐Shelf” Immunity[J]. Advanced Science, 2025, 12(8): 2401287.

IF=10 Sun Y, Peng X, Guan Y, et al. K2FeO4‐Enhanced Photodynamic Therapy of Breast Cancer via In Situ Synthesis of Fe2O3 and O2[J]. Advanced Healthcare Materials, 2025, 14(2): 2402827.

IF=5.8 Zhao H Y, Li K H, Wang D D, et al. A mitochondria-targeting dihydroartemisinin derivative as a reactive oxygen species-based immunogenic cell death inducer[J]. Iscience, 2024, 27(1).
Contact us
Title
Name
*
Country/Region
*
How would you like us to contact you?
*
E-mail
*
Institution
Phone
Where did you learn about HySigen?
Verification code
Change Image
*
Submit

Quote/Order

We will contact you with information about this product. Please let us know how to reach you.
Contact Us


Address: 56 Sugar Creek Blvd Suite 375,
Sugar Land, TX 77478

Email: info@hysigen.com

Telephone: +1 (909) 352-8083 (US)

Accelerate research, empower industry